Neurotech International Limited (ASX:NTI)

Market Cap	14.69M
Revenue (ttm)	2.58M
Net Income (ttm)	-10.60M
Shares Out	1.05B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	307,350
Average Volume	1,072,266
Open	0.0140
Previous Close	0.0130
Day's Range	0.0140 - 0.0140
52-Week Range	0.0120 - 0.0770
Beta	0.35
RSI	42.91
Earnings Date	Aug 26, 2025

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing techno...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NTI

Financial Performance

In 2025, Neurotech International's revenue was 2.58 million, a decrease of -18.75% compared to the previous year's 3.18 million. Losses were -10.60 million, 109.1% more than in 2024.